Radioligand-induced immunogenic cell death: 177Lu-PSMA-617 and 225Ac-PSMA-RLT trigger tumor apoptosis and neoantigen release, enhancing immune recognition and dendritic cell activation (Pouget et al., 2023). Here, FOLH1 is linked to neoplasm.